Namodenoson

also known as CF102 · Chloro-ib-meca · CI-IB-MECA · CL-IB-MECA

Small molecule targets ADORA3 via activation

Developed for: hepatocellular carcinoma · chronic hepatitis C virus infection · cirrhosis of liver · metabolic dysfunction-associated steatohepatitis · pancreatic adenocarcinoma
Investigated by: Can-Fite BioPharma

Trials 6

today NCT06387342 · Ph 2 NCT05201404 · Ph 3 NCT04697810 · Ph 2 NCT02128958 · Ph 2 NCT00790673 · Ph 1/2 NCT00790218 · Ph 1/2

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/22 trials · 1 met primary
Phase 1/2	NCT00790673	Jul 2009 → Jun 2011	chronic hepatitis C virus infection	Can-Fite BioPharma	Completed	No outcome recorded
Phase 1/2	NCT00790218	Feb 2009 → Dec 2012	hepatocellular carcinoma	Can-Fite BioPharma	Completed	Met primary
Phase 23 trials
Phase 2	NCT06387342	Nov 2024 → Jul 2026 overdue	pancreatic adenocarcinoma	Can-Fite BioPharma	Recruiting	No outcome recorded
Phase 2	NCT04697810	Dec 2021 → Apr 2025 overdue	metabolic dysfunction-associated steatohepatitis	Can-Fite BioPharma	Recruiting	No outcome recorded
Phase 2	NCT02128958	Sep 2014 → Nov 2017	hepatocellular carcinoma	Can-Fite BioPharma	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT05201404	Mar 2023 → Feb 2026 overdue	cirrhosis of liver, hepatocellular carcinoma	Can-Fite BioPharma	Recruiting	No outcome recorded
Comparator or background therapy1 trial
Phase 2	NCT02927314 Comparator	Nov 2017 → Mar 2020	metabolic dysfunction-associated steatohepatitis	Can-Fite BioPharma	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 97

Date	Issuer	Release
2026-09-09	Can-Fite BioPharma	Results Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation canfite.com ↗ During treatment, the patient experienced resolution of ascites and regression of esophageal varices.
2026-09-08	Can-Fite BioPharma	Results Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study canfite.com ↗ Blinded overall survival observed across the entire patient population in the Company’s ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC) appears longer than originally anticipated based on the assumptions underlying the study design.
2026-09-02	Can-Fite BioPharma	Results Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study canfite.com ↗
2026-08-17	Can-Fite BioPharma	Results Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer canfite.com ↗
2026-08-12	Can-Fite BioPharma	Regulatory Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates canfite.com ↗ Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs
2026-07-01	Can-Fite BioPharma	Results Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease canfite.com ↗
2026-06-26	Can-Fite BioPharma	Regulatory Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology canfite.com ↗ The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including the Company's lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders.
2026-06-22	Can-Fite BioPharma	Results Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson canfite.com ↗ today announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases.
2026-06-02	Can-Fite BioPharma	Results Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism canfite.com ↗ The Company also reported encouraging clinical observations from its Phase 2a study of namodenoson as a monotherapy in pancreatic cancer.
2026-05-13	Can-Fite BioPharma	Results Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy canfite.com ↗ The Phase 2a study demonstrated a favorable safety profile together with clinical activity manifested by prolonged treatment duration in a subset of patients including treatment extending beyond 16 months
2026-04-30	Can-Fite BioPharma	Results Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months canfite.com ↗ The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile.
2026-03-26	Can-Fite BioPharma	Results Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient canfite.com ↗ A patient with advanced HCC, treated with Namodenoson has reached an overall survival of more than 9 years with complete response to treatment.
2026-03-17	Can-Fite BioPharma	Regulatory Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance canfite.com ↗
2026-03-04	Can-Fite BioPharma	Results Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study canfite.com ↗ The study met its primary endpoint, which was safety, demonstrating that namodenoson was very well tolerated in this heavily pretreated patient population.
2026-02-17	Can-Fite BioPharma	Results Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson canfite.com ↗ The publication reports that namodenoson significantly inhibited adipocyte proliferation and lipid droplet accumulation in a dose-dependent manner.
2026-02-05	Can-Fite BioPharma	Results Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson canfite.com ↗ Throughout the treatment period, Namodenoson contributed to clinical stabilization, allowing the patient to remain a suitable candidate for liver transplantation until a compatible donor organ became available, ultimately resulting in a successful, life-saving liver transplantation.
2025-11-18	Can-Fite BioPharma	Results Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson canfite.com ↗ Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that a patient treated with Namodenoson has reached an overall survival of 9 years to date with complete response to treatment.
2025-09-15	Can-Fite BioPharma	Results Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson canfite.com ↗ The patient, previously reported by Can-Fite to have experienced the disappearance of end-stage liver disease complications while receiving Namodenoson, has now demonstrated a complete resolution of esophageal varices, as confirmed by endoscopic evaluation.
2025-04-17	Can-Fite BioPharma	Regulatory Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients canfite.com ↗ Namodenoson has recently received FDA approval for its first single-patient compassionate use treatment, marking a significant milestone in its clinical journey.
2025-04-14	Can-Fite BioPharma	Results Can-Fite Reports 2024 Financial Results and Clinical Update canfite.com ↗
2025-03-18	Can-Fite BioPharma	Regulatory Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient canfite.com ↗
2025-03-03	Can-Fite BioPharma	Results Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits canfite.com ↗ The article presents compelling preclinical and clinical data demonstrating Namodenoson’s potent anti-ischemic, anti-inflammatory, anti-fibrotic, and anti-toxicity effects across multiple body tissues including the liver, central nervous system, and cardiovascular system.
2025-02-18	Can-Fite BioPharma	Results Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson canfite.com ↗ today announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson under a compassionate use program.
2025-01-27	Can-Fite BioPharma	Regulatory US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug canfite.com ↗ today announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US patent office.
2024-12-04	Can-Fite BioPharma	Results 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug canfite.com ↗
2024-10-09	Can-Fite BioPharma	Regulatory FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer canfite.com ↗ Namodenoson, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the indication of pancreatic cancer, one of the most aggressive malignancies.
2024-09-16	Can-Fite BioPharma	Regulatory Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health canfite.com ↗ today announced that it received approval from the Israeli Ministry of Health (MoH) to conduct Phase IIa clinical trial with orally-administered Namodenoson in the treatment of pancreatic carcinoma.
2024-07-11	Can-Fite BioPharma	Regulatory Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer canfite.com ↗ Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma.
2024-07-01	Can-Fite BioPharma	Results Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson canfite.com ↗
2024-06-24	Can-Fite BioPharma	Results Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver canfite.com ↗ today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin.
2024-05-29	Can-Fite BioPharma	Results Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases canfite.com ↗ It is very interesting that our drug candidates have additional well-defined cardio-protective effect and have the potential to positively influence a broad range of heart diseases.
2024-05-09	Can-Fite BioPharma	Regulatory Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study canfite.com ↗ Currently Can-Fite is enrolling patients for a Phase IIb clinical study in Europe and in Israel and the IND approval by FDA will allow for the recruitment of patients in the US.
2024-04-25	Can-Fite BioPharma	Results Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal canfite.com ↗ The patient participated in the Phase II Liver Cancer Study and has been treated with namodenoson for >7 years under compassionate use program.
2024-04-15	Can-Fite BioPharma	Results Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH canfite.com ↗ The Biomedicines article presents the pre-clinical and clinical activity of Namodenoson and the mechanism of action through which the drug induces the anti-cancer activity and at the same time the liver protective effects.
2024-04-03	Can-Fite BioPharma	Regulatory Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients canfite.com ↗ Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company’s ongoing Phase IIb clinical study.
2024-02-28	Can-Fite BioPharma	Regulatory Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada canfite.com ↗ today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
2023-12-20	Can-Fite BioPharma	Results The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies canfite.com ↗ New data demonstrate that treatment of fat cells (3T3-L1 adipocytes) with Namodenoson leads to modulation of proteins that increase adiponectin level.
2023-11-30	Can-Fite BioPharma	Results Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update canfite.com ↗ Advanced liver cancer patient in prior Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson
2023-11-21	Can-Fite BioPharma	Results Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson canfite.com ↗ Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that a patient who participated in the Phase II Liver Cancer Study and was treated with namodenoson has a complete response and overall survival of 6.9 years (82.8 months).
2023-10-30	Can-Fite BioPharma	Results Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action canfite.com ↗ The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.
2023-09-27	Can-Fite BioPharma	Results Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) canfite.com ↗ Namodenoson treatment resulted in a significant growth inhibition and de-regulation of two signal transduction pathways, the Wnt and the KRAS, both of which are responsible for the etiology and pathology of this devastating disease.
2023-05-30	Can-Fite BioPharma	Results Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) canfite.com ↗ A significant dose-dependent inhibition of pancreatic cancer cell growth was found when the cells were exposed to Namodenoson.
2023-05-02	Can-Fite BioPharma	Results Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists canfite.com ↗ Namodenoson de-regulates the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.
2023-02-14	Can-Fite BioPharma	Results Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo canfite.com ↗ Treatment with Namodenoson resulted in longer overall survival in patients with advanced liver cancer as defined by Child Pugh B (CPB) stage in a statistically significant manner.
2023-01-24	Can-Fite BioPharma	Results Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed canfite.com ↗ In combination with the leading chemotherapy used in pancreatic cancer, gemcitabine, Namodenoson demonstrated a significant additive effect.
2022-12-28	Can-Fite BioPharma	Results Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer canfite.com ↗ The Company will also share the latest findings on a CPB liver cancer patient who remains cancer-free 6 years after she began treatment with Namodenoson.
2022-10-25	Can-Fite BioPharma	Results Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting® canfite.com ↗
2022-08-23	Can-Fite BioPharma	Regulatory Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania canfite.com ↗
2022-06-09	Can-Fite BioPharma	Results Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal canfite.com ↗ Data suggest Piclidenoson and Namodenoson could potentially be the first A3AR agonists to achieve FDA approval and provide clinicians with new oral and safe drugs in the arsenal for fighting psoriasis, liver cancer, and NASH
2022-05-02	Can-Fite BioPharma	Results Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit canfite.com ↗ Radiological data show the disappearance of tumor lesions from a patient treated with Namodenoson who had advanced disease and fully recovered.
2022-03-14	Can-Fite BioPharma	Regulatory Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office canfite.com ↗
2021-12-29	Can-Fite BioPharma	Results Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors canfite.com ↗ Can-Fite’s Namodenoson, a small orally bioavailable drug that binds with high affinity and selectivity to A3AR, was recently found to clear all cancer lesions in a patient treated under an Open Label Extension program of its concluded Phase II study
2021-12-20	Can-Fite BioPharma	Results Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study canfite.com ↗ Under treatment with Namodenoson, the patient has now survived five years, during which time the clinical benefits of treatment have included the disappearance of ascites, normal liver function, and the disappearance of peritoneal carcinomatosis leading to complete clearance of all cancer lesions.
2021-10-21	Can-Fite BioPharma	Results Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal canfite.com ↗ The article includes highlights from Can-Fite’s Phase IIa NASH study of Namodenoson which achieved its study endpoints including significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects.
2021-06-02	Can-Fite BioPharma	Regulatory Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson canfite.com ↗
2021-02-22	Can-Fite BioPharma	Results New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson canfite.com ↗ Additional findings show disappearance of ascites, normal liver function and good quality of life.
2021-01-08	Can-Fite BioPharma	Results Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers canfite.com ↗ Even though the trial did not meet its primary endpoint, in patients with a CPB score of 7, Namodenoson was associated with a significant improvement in 12-month overall survival and 2 patients are still under treatment for more than 3.5 years.
2020-11-16	Can-Fite BioPharma	Results Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference canfite.com ↗ As a result of the study, 25 mg was determined to be the optimal dose.
2020-09-30	Can-Fite BioPharma	Results Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference canfite.com ↗ FLD/NASH study achieved its efficacy and safety endpoints in a dose dependent and statistically significant manner.
2020-06-30	Can-Fite BioPharma	Results Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period canfite.com ↗ As a whole, the data show that Namodenoson at the 25 mg dose produced statistically significant results in all measures of efficacy, while also having a strong safety profile and well tolerated.
2020-06-04	Can-Fite BioPharma	Regulatory Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer canfite.com ↗ Having completed its meeting with the SAWP, Can-Fite now has sufficient regulatory input to conduct a registration trial in accordance with the requirements of both the U.S. and the European Union.
2020-05-21	Can-Fite BioPharma	Regulatory Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office canfite.com ↗
2020-05-18	Can-Fite BioPharma	Results Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis canfite.com ↗ Most significantly, a more recent in-depth review of the Phase II data reveal 25 mg of Namodenoson was found to resolve significantly all cases of NASH, representing 25% of the 25 mg treated group, as compared to an increase in new NASH cases in the placebo group from a baseline of 0 to 5.9%.
2020-04-07	Can-Fite BioPharma	Results Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson canfite.com ↗ The study shows Namodenoson has therapeutic effects with a good safety profile and is a very strong candidate for continued clinical development in the treatment of NAFLD/NASH
2020-03-16	Can-Fite BioPharma	Results Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson canfite.com ↗ Results of treatment in this patient group indicate that Namodenoson was found to have a good safety profile and was well tolerated, with no severe adverse events reported.
2020-03-03	Can-Fite BioPharma	Regulatory Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson canfite.com ↗ Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it is submitting its annual Drug Safety Update Reports (DSUR) for both Piclidenoson and Namodenoson to the governing health regulatory agencies where its drug candidates are currently treating patients.
2020-02-24	Can-Fite BioPharma	Regulatory Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications canfite.com ↗ Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a patent application for its drug candidate Namodenoson to be used as a combination therapy with checkpoint inhibitors.
2020-02-13	Can-Fite BioPharma	Regulatory Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson canfite.com ↗
2020-01-07	Can-Fite BioPharma	Results Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer canfite.com ↗ Can-Fite’s completed Phase II liver cancer study found that Namodenoson increased overall survival in HCC patients with Child Pugh B7 (CPB7), the largest subpopulation of the study, as compared to placebo, even though the trial did not meet its primary endpoint.
2020-01-03	Can-Fite BioPharma	Results New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss canfite.com ↗ today announced pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadi’s lab demonstrate that Namodenoson induces weight loss in experimental models and normalizes glucose levels.
2019-10-10	Can-Fite BioPharma	Results Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine canfite.com ↗ The study data show that Namodenoson induced significant anti‑inflammatory, anti‑steatotic and anti‑fibrotic effects mediated by de-regulation of the Wnt/β-catenin pathway, known to be active in NAFLD/NASH.
2019-09-23	Can-Fite BioPharma	Results Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference canfite.com ↗ While the Phase II study did not achieve its primary endpoint of overall survival in the whole population (n=78), superiority in overall survival was found in the largest study subpopulation of patients who were classified Child Pugh B7 (CPB7, n=56)
2019-06-03	Can-Fite BioPharma	Results Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session canfite.com ↗ While the Phase II study did not achieve its primary endpoint of overall survival in the whole population (n=78), superiority in overall survival was found in the largest study subpopulation of patients who were classified Child Pugh B7 (n=56) based on severity of disease compared to the placebo treated group.
2019-03-26	Can-Fite BioPharma	Results Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson canfite.com ↗ At the same time, superiority in overall survival was found in the largest study subpopulation of CPB7 (n=56) and in secondary end points in the whole population, including objective response measured by CT or MRI.
2019-01-30	Can-Fite BioPharma	Results Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal canfite.com ↗ The article presents data from numerous studies that show adenosine’s role in inhibiting inflammatory cytokine production.
2019-01-08	Can-Fite BioPharma	Results Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent canfite.com ↗ New pre-clinical studies of Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes, functioning as lipid producing cells and are also responsible for fat storage.
2018-11-30	Can-Fite BioPharma	Results Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update canfite.com ↗ Prolonged longevity of patients in our Namodenoson Phase II advanced liver study was reported this quarter.
2018-09-12	Can-Fite BioPharma	Results Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD) canfite.com ↗ Can Fite will present data generated recently in histological studies utilizing the CCL4 NAFLD/NASH model, demonstrating a significant decrease in liver fibrosis upon chronic treatment with Namodenoson, as measured by Sirius Red staining followed by morphometric digital analysis.
2018-06-11	Can-Fite BioPharma	Results Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson canfite.com ↗ In an experimental non-alcoholic steatohepatitis (NASH) CCL4 model, Namodenoson had a highly significant effect against inflammation, necrosis, fibrosis and biliary hyperplasia, while treating the animals orally with the drug.
2018-04-09	Can-Fite BioPharma	Results Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL) canfite.com ↗ We are excited that our pre-clinical data have demonstrated robust anti-inflammatory, anti-fibrogenic and anti-steatotic effects, supporting our development for this indication.
2018-02-28	Can-Fite BioPharma	Results Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson canfite.com ↗ Recent safety data showed that Namodenoson has a favorable profile and lack of hepatotoxicity in patients.
2018-02-22	Can-Fite BioPharma	Results Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile canfite.com ↗ The Namodenoson development program includes patients with advanced hepatocellular carcinoma (liver cancer), in whom serious adverse events, cancer progression, and mortality are expected and occurred; nevertheless, despite the underlying illness of this population, no SARs or SUSARs were reported during 2017.
2017-10-16	Can-Fite BioPharma	Results Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C. canfite.com ↗ In this study the anti-inflammatory and anti-fibrogenic effects of Namodenoson are demonstrated in a CCl4 mouse model manifested by a decrease in ALT, NKT cell activity in the liver and signaling proteins including α-SMA, PI3K and p-STAT-1.
2017-06-01	Can-Fite BioPharma	Results New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017 canfite.com ↗ Data show that Namodenoson both prevented progression and inhibited liver fibrosis to obtain fibrosis regression.
2017-02-28	Can-Fite BioPharma	Results New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis canfite.com ↗ today announced new data that show its liver disease drug candidate Namodenoson (CF102) prevented liver (hepatic) fibrosis progression in preclinical studies.
2016-12-16	Can-Fite BioPharma	Results New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH canfite.com ↗ today announced that new preclinical data show its liver disease drug candidate Namodenoson (CF102) inhibited, in a dose dependent manner, the growth and proliferation of the liver fibrosis cells.
2016-11-16	Can-Fite BioPharma	Regulatory American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102 canfite.com ↗ the United States Adopted Names Council (USAN) of the American Medical Association and the World Health Organization's International Nonproprietary Name (INN) group have accepted the proposed generic name "Namodenoson" for its drug candidate, CF102.
2016-10-13	Can-Fite BioPharma	Regulatory Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH canfite.com ↗
2016-09-20	Can-Fite BioPharma	Results Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal canfite.com ↗ The article reports the results of preclinical studies conducted by Can-Fite, showing the Company's liver cancer drug candidate CF102 protects the liver from ischemia/reperfusion injury and regenerates liver cells following partial hepatectomy.
2015-11-23	Can-Fite BioPharma	Results Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH) canfite.com ↗ Results from our recently concluded preclinical study of CF102 in liver disease revealed compelling data.
2015-10-12	Can-Fite BioPharma	Regulatory European Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer canfite.com ↗ Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.
2015-09-17	Can-Fite BioPharma	Regulatory U.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer canfite.com ↗ Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the Company's drug candidate CF102 Fast Track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer.
2015-05-11	Can-Fite BioPharma	Regulatory Can-Fite's Phase II Liver Cancer Trial Approved in Europe canfite.com ↗
2015-04-20	Can-Fite BioPharma	Regulatory Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer canfite.com ↗
2014-07-10	Can-Fite BioPharma	Regulatory Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient canfite.com ↗ Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program.
2014-06-02	Can-Fite BioPharma	Regulatory Can-Fite Announces that the US FDA has Agreed with its Phase II Liver Cancer Protocol canfite.com ↗ Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.
2014-04-29	Can-Fite BioPharma	Regulatory Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study canfite.com ↗ The FDA has granted Orphan Drug designation to CF102 in this indication.

All press releases naming this drug 159 releases

Date	Issuer	Release
Show all 159 releases opens the full record — a long page

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	Namodenoson	“Namodenoson, an A3 adenosine receptor (A3AR) agonist, improved liver function/pathology in non-alcoholic steatohepatitis (NASH) preclinical models.” PMID 34671996 ↗ Oct 2021 3 NCT06387342 ↗ NCT05201404 ↗ NCT04697810 ↗
Known as	CF102	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02128958 ↗ 2 NCT00790218 ↗ NCT00790673 ↗
Known as	Chloro-ib-meca	ChEMBL registry synonym — accepted as the source's own label CHEMBL431733 ↗
Known as	CI-IB-MECA	ChEMBL registry synonym — accepted as the source's own label CHEMBL431733 ↗
Known as	CL-IB-MECA	ChEMBL registry synonym — accepted as the source's own label CHEMBL431733 ↗
Action	Activate	“Adenosine A3 receptor agonist” CHEMBL431733 ↗ 1 “CF102, an A(3)AR agonist” PMID 23299770 ↗ Jan 2013
Modality	Small molecule	— CHEMBL431733 ↗
Route	Oral	“CF102 given orally (1, 5, and 25 mg BID)” PMID 23299770 ↗ Jan 2013
Target	ADORA3	“Adenosine A3 receptor agonist” CHEMBL431733 ↗